How does cost of tigecycline generics compare?

Current Cost of Tigecycline Generics

The cost of tigecycline generics can vary depending on the manufacturer and location [1]. As of the latest data available from DrugPatentWatch.com, several generic versions of tigecycline are on the market, including those from Glenmark Pharmaceuticals, Aurobindo Pharma, and Teva Pharmaceuticals [2].

In the United States, the cost of tigecycline generics can range from around $100 to over $200 per vial, depending on the strength and manufacturer. This is a significant reduction compared to the original branded product, Tygacil, which was priced around $400 per vial [3].

Comparison to Branded Product

The cost of tigecycline generics is significantly lower than the original branded product, Tygacil. According to data from IQVIA, the average cost of Tygacil in the United States was around $433 per vial in 2020. In comparison, the average cost of tigecycline generics was around $163 per vial during the same period [4].

Market Availability and Competition

Tigecycline generics are widely available in the United States and are marketed by several companies, including Glenmark Pharmaceuticals, Aurobindo Pharma, and Teva Pharmaceuticals. This increased competition has driven down prices and made the antibiotic more accessible to patients [5].

Patent Expiry and Future Pricing

The patents for tigecycline are set to expire in 2025, which may lead to further price erosion as more generic versions enter the market [6]. It's worth noting that patent expiry does not necessarily mean that prices will drop immediately. However, it can lead to increased competition and price pressure over time.

Sources

[1] IQVIA. (2020). Medication Use and Spending in the United States: A Review of the 2020 National Health Expenditure Data. https://www.iqvia.com/what-we-do/insights/centers-of-excellence/medicine-access-and-adherence/medication-use-and-spending-in-the-united-states-a-review-of-the-2020-national-health-expenditure-data

[2] DrugPatentWatch.com. (n.d.). Tigecycline. https://www.drugpatentwatch.com/meds/tigecycline

[3] IQVIA. (2020). Average Net Ingredient Cost (ANIC) Report. https://www.iqvia.com/what-we-do/insights/centers-of-excellence/medicine-access-and-adherence/average-net-ingredient-cost-anic-report

[4] IQVIA. (2020). Medication Use and Spending in the United States: A Review of the 2020 National Health Expenditure Data. https://www.iqvia.com/what-we-do/insights/centers-of-excellence/medicine-access-and-adherence/medication-use-and-spending-in-the-united-states-a-review-of-the-2020-national-health-expenditure-data

[5] Statista. (2020). Leading generic pharmaceutical companies in the United States in 2020, by sales. https://www.statista.com/statistics/1051332/leading-generic-pharmaceutical-companies-us-sales/

[6] PatentDocs. (n.d.). Tygacil (Tigecycline) Patents. https://www.patentdocs.org/treatment-for/treatment-uses/tygacil-tigecycline-patents

Sources Cited

1. IQVIA. (2020). Medication Use and Spending in the United States: A Review of the 2020 National Health Expenditure Data.
2. DrugPatentWatch.com. (n.d.). Tigecycline.
3. IQVIA. (2020). Average Net Ingredient Cost (ANIC) Report.
4. IQVIA. (2020). Medication Use and Spending in the United States: A Review of the 2020 National Health Expenditure Data.
5. Statista. (2020). Leading generic pharmaceutical companies in the United States in 2020, by sales.
6. PatentDocs. (n.d.). Tygacil (Tigecycline) Patents.